Format

Send to

Choose Destination
Clin Breast Cancer. 2018 Aug;18(4):305-312.e3. doi: 10.1016/j.clbc.2017.11.007. Epub 2017 Nov 21.

Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status.

Author information

1
First Department of Pathology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece; Department of Pathology, "Saint Savvas" Cancer Hospital of Athens, Athens, Greece.
2
Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
3
First Department of Pathology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
4
First Department of Pathology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Oncology and Pathology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
5
Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: ascorilas@biol.uoa.gr.

Abstract

BACKGROUND:

Aberrations in microRNA levels seem to provide valuable information regarding breast cancer prognosis and therapy. In this study, we sought to analyze miR-29b expression in breast tumors and thus explore its clinical value.

MATERIALS AND METHODS:

One hundred twenty-one malignant and 56 benign breast tissue specimens were collected and subjected to extraction of total RNA, which was polyadenylated and reverse transcribed to cDNA. Subsequently, a highly sensitive quantitative real-time polymerase chain reaction protocol was developed and miR-29b levels, estimated via the comparative CT method, were finally subjected to comprehensive statistical analysis.

RESULTS:

MiR-29b levels did not differ between the analyzed benign and malignant breast tissue specimens, but were found to be significantly (P = .010) decreased in invasive ductal adenocarcinomas compared with their lobular counterparts, albeit receiver operating characteristics curve analysis did not verify the latter correlation. Additionally, miR-29b expression was elevated in samples with positive estrogen receptor status (P = .021) in the overall population, whereas it was negatively correlated (P = .035) with primary tumor staging in the ductal subset and increased in poorly-differentiated tumors of lobular origin (P = .041). Furthermore, Kaplan-Meier and Cox regression analyses showed that patients with ductal carcinoma and elevated miR-29b levels had a significantly longer disease-free survival (P = .010) and a lower risk to relapse (hazard ratio = 0.35, 95% confidence interval, 0.15-0.81; P = .014).

CONCLUSION:

Our results provide evidence that miR-29b levels constitute a promising biomarker of favorable prognosis for patients with invasive ductal breast carcinoma and imply that its expression status might be affected by the histological origin of breast malignancy.

KEYWORDS:

Lobular; Mammary gland neoplasia; MicroRNAs; Molecular tumor markers; Quantitative real-time polymerase chain reaction

PMID:
29422258
DOI:
10.1016/j.clbc.2017.11.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center